WCCT Global, an international specialized CRO, and Medelis, a specialty oncology CRO, have merged to offer U.S. and international clients access to an expanded depth and breadth of clinical research offerings.

"The complex and rapidly growing oncology drug development market in the US, Europe, and Asia requires unique insight and expertise and an eye toward the future, all of which we now offer through this merger," said Dr. Kenneth Kim, founder and CEO of WCCT Global. "We're committed to delivering world-class clinical research solutions to achieve our vision of becoming the global leader in the development of specialized medicines and therapies."

Medelis will continue to provide the highest quality clinical research for all of Medelis' current and future studies. Bill Taaffe, the current president of Medelis and former president and CEO of Icon Clinical Research-U.S., will continue to lead Medelis.

"We now offer the solution for the many sponsors who have been asking for a single specialty oncology CRO to help them navigate all of the complexities of taking oncology and immuno-oncology drugs into the clinic in the U.S., Europe, and Asia," said Bill Taaffe, president of Medelis.

WCCT Global offers in-house project management, clinical monitoring, biostatistics and data management, an extensive investigator and patient recruitment network, clinical pharmacology units, and a translational medicine team for handling all aspects of regulatory affairs. The merger adds to these corporate offerings the extensive oncology expertise of Medelis and the experience of designing and managing preclinical and phase I through phase IV studies at over 400 sites in North America andEurope.

"The addition of Medelis not only creates a more robust offering for our current and future clients, it also creates a stronger company with multiple synergies to fuel our future growth," said Ron Linares, CFO of WCCT Global.